Brief: Aadi Bioscience Q3 product sales USD 5.959 million

Whitehawk Therapeutics

08/11/2023 13:11

Nov 8 (Reuters) - Aadi Bioscience Q3 net income USD -16.302 million.
* Q3 operating income USD -17.849 million
* Q3 product sales USD 5.959 million
* Q3 pretax profit USD -16.302 million
* Q3 operating expenses USD 23.808 million